Avanos Medical (AVNS)
(Delayed Data from NYSE)
$21.18 USD
+1.79 (9.23%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $21.18 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.18 USD
+1.79 (9.23%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $21.18 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth A Momentum C VGM
Zacks News
Avanos Medical (AVNS) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -29.41% and 12.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.
AVNS vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
AVNS vs. EW: Which Stock Is the Better Value Option?
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.
Baxter (BAX) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
Intuitive Surgical (ISRG) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Avanos' (AVNS) Latest Buyout to Boost Its RF Product Offering
by Zacks Equity Research
Avanos' (AVNS) latest acquisition is expected to strengthen its foothold with a comprehensive suite of RF offerings.
Masimo (MASI) Down 6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos (AVNS) Q1 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Chronic Care segment, its overall first-quarter results reflect soft performances.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Avanos Medical (AVNS) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -3.57% and 1.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
National Vision's (EYE) share price is likely to grow following the company's efforts to expand remote capabilities and investments in doctor recruiting and retention efforts.
Hologic (HOLX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 20.45% and 6.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.
Integra's (IART) Q1 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.
Align Technology (ALGN) Q1 Earnings Beat, Margins Contract
by Zacks Equity Research
Align Technology (ALGN) delivers better-than-expected revenues and earnings in the first quarter of 2023 but suffers significant foreign currency woes.
Boston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised
by Zacks Equity Research
Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.
LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on the increased adoption of its premium RESILIA technologies.
3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adaptive Biotechnologies (ADPT) and Avanos Medical (AVNS) have performed compared to their sector so far this year.